Nuvalent, INC Form 4 insider transactions

James E Flynn and 7 others reported changes in beneficial ownership of Nuvalent, Inc. common stock on July 15, 2026.

Michael L. Meyers, a Director of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

Alexandra Balcom, Chief Financial Officer of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

Sapna Srivastava, a Director of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

Christy J. Oliger, a Director of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

Ron Squarer, a Director of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

Christopher Durant Turner, Chief Medical Officer of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

Darlene Noci, Chief Development Officer of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

Benjamin Lane, See Remarks of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

Henry E. Pelish, Chief Scientific Officer of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

James Richard Porter, President and CEO and a Director of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

Deborah Ann Miller, Chief Legal Officer of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

Anna Protopapas, a Director of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

Grant C. Bogle, a Director of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

Cameron Wheeler, a Director of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

Nuvalent, Inc. reports a Form 4 filing detailing a transaction by Chief Scientific Officer Henry E. Pelish involving the sale of 2,111 shares of Class A Common Stock.

Nuvalent, Inc. President and CEO James Richard Porter sold 30,000 shares of Class A Common Stock for $18.93 per share, as part of a pre-arranged trading plan.

Nuvalent's Chief Development Officer, Darlene Noci, executed a Rule 10b5-1 trading plan, resulting in the sale of Nuvalent Inc. Class A Common Stock.

Nuvalent's Chief Financial Officer, Alexandra Balcom, executed a series of stock transactions under a pre-arranged trading plan.

Nuvalent, Inc. reports a Form 4 filing detailing stock transactions by Chief Development Officer Darlene Noci, including the sale of shares acquired via stock options under a pre-arranged trading plan.

James E. Flynn, a director and significant stakeholder in Nuvalent, Inc., reported the acquisition of 3,444 shares of Class A Common Stock on June 16, 2026.

Nuvalent, Inc. reports a Form 4 filing detailing a transaction by Director Cameron Wheeler.

Nuvalent, Inc. reports a Form 4 filing detailing a transaction by Director Sapna Srivastava, acquiring 3,444 shares of Class A Common Stock.

Nuvalent, Inc. reports a Form 4 filing detailing a transaction by Director Ron Squarer.

Nuvalent, Inc. Director Anna Protopapas acquired 3,444 shares of Class A Common Stock through restricted stock units.

Nuvalent, Inc. reports a Form 4 filing detailing a transaction by Director Christy J. Oliger, acquiring 3,444 shares of Class A Common Stock.

Michael L. Meyers, a Director at Nuvalent, Inc., reported the acquisition of 3,444 shares of Class A Common Stock on June 16, 2026.

Nuvalent, Inc. reports that Director Grant C. Bogle acquired 3,444 shares of Class A Common Stock through restricted stock units.

Nuvalent, Inc. Chief Development Officer Darlene Noci exercised stock options and sold 20,000 shares of Class A Common Stock.

Nuvalent CEO James Richard Porter exercised options and sold 30,000 shares of Class A Common Stock under a 10b5-1 plan.